Advanced Filters
noise

metastatic-cancer Clinical Trials

A listing of metastatic-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,244 clinical trials
H Hyongbum Henry Kim, M.D.

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

This is a combined prospective and retrospective observational study aiming to validate a highly sensitive and specific blood-based method for the early diagnosis and post-treatment monitoring of multiple cancers. The study leverages a newly developed sequencing method to improve the detection of circulating tumor DNA (ctDNA) in blood, focusing on …

19 years of age All Phase N/A
C Cancer Clinical Trials Team

National Cancer Institute "Cancer Moonshot Biobank"

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from …

13 years of age All Phase N/A
A Andrea Berget

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant …

19 - 110 years of age All Phase N/A
C Costantino Errani, MD, PhD

Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones

The aims of this study are to collect prospective data on the natural history of bone metastases (BMs) and skeleta related events (SREs),

years of age All Phase N/A
A Anita Sayar

Prospective Validation of a Points Score System Predicting 30-day Survival

This is a one-stage single-arm phase II clinical trial designed to prospectively test the survival prediction tool as developed by Lee et al on patients referred to radiation oncology for palliative treatments. Survival prediction score based on objective data including laboratory values, attendance to emergency room, and primary cancer origin …

18 years of age All Phase N/A
P Philip Wong, MD

Patient Reported Outcomes/Metrics Program Trial

This is an observational study to investigate if it is feasible to recruit 100 patients receiving radiotherapy (RT) to metastatic disease to wear Hexoskin and if Hexoskin will facilitate the monitoring, detection and early treatment of RT-related side effects.

18 years of age All Phase N/A
Z Zhengfei Zhu, MD

Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model

A pre-metastatic target organ/primary lesion fusion radiomics model was developed based on the "soil-seed" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ/primary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal …

18 - 75 years of age All Phase N/A
M Mustafa Onur Karaca, Assc. Proff

Metastatic Pathologic Fractures, Short Term Results

This is a single center prospective study to compare the short term results of prosthesis, nail and plate-screw surgeries for metastatic pathologic fractures.

years of age All Phase N/A
R Robert Lewandowski, MD

Optimizing Y90 Therapy for Radiation Lobectomy

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic …

18 years of age All Phase N/A
R Roberto Iacovelli, MD, PhD

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Prostate cancer remains the most common malignancy in men in Europe. Over the last two decades, the treatment landscape for both localized and metastatic prostate cancer has been revolutionized. For patients with metastatic castration-sensitive prostate cancer (mCSPC), the primary treatment objectives are to delay progression to metastatic castration-resistant prostate cancer …

18 years of age Male Phase N/A

Simplify language using AI